Imsidolimab

Name: Imsidolimab in Generalized pustular psoriasis: Definition and etiology
Published: 2026-09-14T15:39:06-04:00

Generalized pustular psoriasis

Manufacturer: Vanda Pharmaceuticals
Regulatory submission: BLA submitted December 2025
Launch: Anticipated in the first half of 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description

Definition and etiology

2 evidence topics · 2 sources

Definition

“Generalized Pustular Psoriasis is a systemic inflammatory disease characterized by cutaneous erythema and macroscopically visible sterile pustules.” (opens the source at this quote in a new tab)

Identified flare triggers

“stress (19.4–21.4%), infections (19.4–21.4%), and treatment withdrawal (7.1–20.0%; none due to the withdrawal of steroids)” (opens the source at this quote in a new tab)